City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
  PROFILE 
The following is a list of available studies directed by  Leslie Popplewell, MD  
Search results:  5  Clinical trial(s) found  (Page 1 of 1 )
Results per page: 25 50 100 All 1-5 Trials Jump to page:

COH Protocol Number: 14231 ClinicalTrials.gov Number: NCT02220842

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  A Phase 1b Sudy of the Safety and Pharmacology of MPDL3280A Administered with Obinutuzamab in Patients with Relpased/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

COH Protocol Number: 13277 ClinicalTrials.gov Number: NCT02051257

Principal Investigator: Leslie Popplewell, MD
Sponsor: NCI Approved External Peer Review

Title:  Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

COH Protocol Number: 13232 ClinicalTrials.gov Number: NCT01802879

Principal Investigator: Leslie Popplewell, MD
Sponsor: Industrial

Title:  An Open-Label Multi-Center Single Agent Panobinostat Roll-Over Protocol for Patients who have Completed a Previous Novartis-Sponsored Panobinostat Study and are Judged by the Investigator to Benefit from Continued Single Agent Panobinostat Treatment

COH Protocol Number: 12336

Principal Investigator: Leslie Popplewell, MD
Sponsor: Institutional

Title:  Evaluation of Peripheral Blood and/or Bone Marrow Aspirate from Patients with Intermediate Grade B-Cell Non-Hodgkins Lymphoma after Autologous Hematopoietic Cell Transplant for the Study of Immune Cell Sub-Population Engraftment

COH Protocol Number: 12260 ClinicalTrials.gov Number: NCT01729806

Principal Investigator: Leslie Popplewell, MD
Sponsor: NCI Approved External Peer Review

Title:  PHI-69, NCI #9197: A Phase I study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

 
Results per page: 25 50 100 All 1-5 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.